TempraMed’s distributor in Panama didn’t wait for a photo op. The company’s own press release notes a first bulk commercial order already fulfilled into Panamanian clinics and pharmacies, the same week the distribution agreement itself became official. It’s the latest in a string of country and channel additions the small Vancouver medtech company has closed since January, from a national pharmacy chain in Israel to a US telemedicine network built around GLP-1 patients.
TempraMed Converts Its Panama LOI Into a Definitive Distribution Deal
TempraMed Technologies (CSE: VIVI) (OTCQB: TMPTF) announced on August 18 that it has executed a definitive exclusive distribution agreement with TEM Consulting International S.A., converting a previously announced letter of intent into a binding commercial relationship. TEM will serve as TempraMed’s exclusive distributor across Panama, moving products into clinics and pharmacies nationwide. TEM has operated in Panama since 2014, works directly with the country’s public healthcare system including the Caja de Seguro Social and Ministerio de Salud, and already distributes for established medical supply brands including Medline, Dynarex, and Reach Surgical, giving TempraMed access to existing institutional relationships rather than a cold start.
CEO Ron Nagar framed the deal as proof of execution rather than just another signed agreement, noting that TEM is already moving product into the market. That distinction matters for a small-cap company: plenty of micro-cap medtechs announce distribution LOIs that never convert into actual product on shelves. TempraMed’s release specifically highlights a first bulk order already fulfilled, which is a more concrete signal than the agreement itself.
The Panama Deal Fits a Broader International Build-Out
Panama is not an isolated move. Since January, TempraMed has added a national pharmacy rollout across Israel’s Super-Pharm chain, initial commercial shipments to Maccabi Healthcare Services pharmacies, and a partnership with Meuhedet Health Services, an Israeli HMO covering more than one million lives. In the US, the company signed a strategic partnership with Stealth Health, a telemedicine platform operating across all 50 states, integrating TempraMed’s products into a direct-to-patient and white-label network that already serves patients on hormone therapy, peptide therapy, and GLP-1 medications, all of which require careful temperature management. A separate US media partnership with Dr. Phil’s Envoy Media gives the company access to a claimed monthly audience above 19 million.
TempraMed also secured a Brazilian patent covering its VIVI Box platform earlier this year and opened an additional manufacturing facility in Florida to expand production capacity. Taken together, the pattern looks less like a single deal and more like a company deliberately building parallel distribution channels across several continents at once.
The Products Behind the Expansion
TempraMed’s portfolio centers on patented, FDA-registered thermal insulation devices that protect temperature-sensitive medications without batteries or external power. VIVI Cap and VIVI Cap Smart target insulin storage, VIVI Epi is shaped to fit EpiPen and Adrenaclick auto-injectors, and VIVI Med, launched in January, extends the platform to vials and biologics, a category that includes the fast-growing class of GLP-1 weight loss and diabetes drugs. The pitch to patients and healthcare providers is straightforward: keep injectable medications within a safe temperature range during travel and everyday use, without refrigeration or charging.
TempraMed’s Revenue Targets and What to Watch
TempraMed’s own investor materials lay out an aggressive growth trajectory: $2.2 million in revenue for 2024, a projected $5.0 million for 2025, and a projected roughly $19 million for 2026, with cash flow positive targeted for this year. These are company-provided projections, not audited or independently verified figures, and should be read as management’s stated targets rather than confirmed results. TempraMed uplisted to the OTCQB Venture Market and achieved DTC eligibility on July 30, a move specifically aimed at widening access to US investors as international deal flow accelerates.
The open question is execution, not ambition. Running distribution conversations and manufacturing scale-up across Panama, Israel, the US, and Brazil simultaneously is a lot for a company of TempraMed’s size, and a CSE-listed micro-cap operating on that many fronts at once carries real execution risk even when each individual deal looks solid on its own. Whether 2026 revenue lands anywhere near the company’s stated target will be the clearest signal of whether this expansion pattern is translating into an actual, durable business.
Sources
- TempraMed Technologies / Newsfile: TempraMed Executes Definitive Exclusive Distribution Agreement with TEM in Panama, August 18, 2026
- BioSpace: TempraMed Announces Strategic Partnership with Stealth Health, a Leading Telemedicine Platform for Longevity and Wellness, August 4, 2026
- TempraMed Technologies company news archive, TMX Newsfile
- TempraMed Investors page: company revenue projections and corporate overview
Editorial Disclosure
This article is based entirely on publicly available information including company press releases and investor materials. The security discussed is TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY). aktiego.com has not received any compensation from TempraMed Technologies, its management, investor relations representatives, or any third party. No staff member or principal of aktiego.com holds a position in this security at the time of publication.
Revenue figures cited for 2025 and 2026 are company-provided projections from TempraMed’s own investor materials, not audited financial statements or independently verified results; only the 2024 figure ($2.2 million) is described by the company as an actual reported result. Forward-looking statements regarding the Panama distribution agreement, including expected scope, effectiveness, and demand, are TempraMed’s own characterizations and are subject to the risks the company itself discloses in its public filings, including its ability to secure additional financing, regulatory and import requirements in each new market, and competitive developments in temperature-controlled medication storage. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the accuracy of TempraMed’s press releases, per the company’s own cautionary disclosure. CSE-listed micro-cap securities carry higher execution and liquidity risk than larger-cap, more established companies; TempraMed’s ability to simultaneously scale distribution across multiple new international markets has not yet been demonstrated over a full fiscal year.
Small cap and micro-cap stocks listed on the CSE, TSX, TSXV, and Nasdaq are speculative investments carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.
